MAPT and Alzheimer disease: Because active immunization with full-length Aβ induced meningitis in clinical trials by a cell-mediated type 1 helper T cell (Th1) immune response [15, 16], the second generation of AD vaccines was developed by conjugating a B-cell epitope of tau or Aβ with a carrier [17, 18].